"Fourteen Months of Bloody Diarrhea. Two Medications That Did Not Work. Steroids She Could Not Stop Taking - and a Plan to Start a Family That She Was Not Ready to Give Up."
Ms. Liu had always been the kind of person who made things work.
A 32-year-old human resources manager at a multinational company, she had built her career on her ability to navigate complexity - to find solutions where others saw obstacles, to keep things moving when everything around her was in motion. She was organized, resilient, and deeply private about the things that were hard.
The colitis had started fourteen months before she came to Shanghai. The bloody diarrhea, the urgency, the cramping that woke her at night - she had managed it, the way she managed everything, by following the treatment plan she had been given. Mesalazine 3 grams a day. Topical enemas. Neither worked. Then prednisolone - 40 mg to start, which brought relief, but every time the dose came down below 15 mg, the symptoms returned. She had been on steroids for months. Her face had changed. Her sleep had changed. Her energy had changed. And she and her husband had been planning to start a family within two years.
She needed a gastroenterologist who understood not just her disease, but her life.
Her colonoscopy told the story precisely: diffuse mucosal hyperemia, edema, granular changes, and loss of vascular pattern from the rectum to the ileocecal valve, with multiple shallow ulcerations. Mayo endoscopic score 3 - severe active disease across the entire colon. Histology confirmed crypt architectural distortion, goblet cell depletion, and acute and chronic inflammatory infiltrate, with no dysplasia or malignant change. Her CRP was 18 mg/L; fecal calprotectin 1050 micrograms per gram; hemoglobin 102 g/L; albumin 36 g/L. Abdominal MRI excluded toxic megacolon and perforation.
The multidisciplinary team - gastroenterology, reproductive endocrinology, nutrition, psychology, and clinical pharmacy - reviewed her case together. Their consensus was clear: steroid-dependent extensive colitis UC with failure of conventional therapy; clear indication for biologic escalation; treatment selection must balance mucosal healing targets with her near-term fertility plans, prioritizing a gut-selective agent with robust pregnancy safety data.
Her family brought her to Shanghai and sought care from Dr. Ran Zhihua, Director of the IBD Center at Renji Hospital, Shanghai Jiao Tong University School of Medicine, through China Medical Concierge - Shanghai (CMCS).
Understanding Steroid-Dependent Ulcerative Colitis and Biologic Therapy: Why Specialist Expertise Changes Everything
Ulcerative colitis is a chronic inflammatory disease of the colon that requires lifelong management - but not all UC is the same, and not all treatment decisions are straightforward. In steroid-dependent extensive colitis with fertility considerations, the choice of biologic agent and the design of the monitoring pathway are as important as the decision to escalate:
- Steroid dependence defines a treatment failure that requires escalation - steroid dependence is defined as the inability to reduce corticosteroid doses below the equivalent of prednisolone 10 mg/day within three months of starting steroids, or relapse within three months of stopping; it is a recognized indication for biologic therapy escalation under international guidelines (ECCO, AGA, ACG); continued steroid exposure carries cumulative risks of osteoporosis, adrenal suppression, metabolic syndrome, and infection that are unacceptable as a long-term management strategy
- Vedolizumab's gut selectivity is its defining clinical advantage - vedolizumab is an anti-integrin monoclonal antibody that selectively blocks the alpha-4-beta-7 integrin on gut-homing lymphocytes, preventing their migration into the intestinal mucosa; unlike anti-TNF agents (infliximab, adalimumab), vedolizumab does not suppress systemic immunity - it acts exclusively in the gut; this gut selectivity translates into a favorable safety profile, particularly for opportunistic infections, and makes it the preferred first-line biologic in patients with infection risk factors, prior malignancy, or - critically - pregnancy plans
- Treat-to-Target strategy transforms IBD management from symptom control to disease modification - the STRIDE-II consensus framework defines treatment targets that go beyond symptom relief: clinical remission (Mayo score 2 or below), endoscopic mucosal healing (Mayo endoscopic score 0-1), and normalization of fecal calprotectin; achieving mucosal healing - not just symptom control - is associated with significantly lower rates of disease progression, hospitalization, colectomy, and colorectal cancer; Treat-to-Target requires systematic monitoring at defined time points and willingness to adjust therapy based on objective endpoints, not just patient-reported symptoms
- Therapeutic drug monitoring optimizes biologic dosing and predicts long-term outcomes - vedolizumab trough concentrations correlate with clinical and endoscopic outcomes; patients with trough levels in the therapeutic range (10-20 micrograms per mL) at week 22 have significantly higher rates of sustained remission and mucosal healing; therapeutic drug monitoring (TDM) also detects anti-drug antibody formation - the primary mechanism of secondary treatment failure - allowing proactive dose optimization before clinical relapse occurs
- IBD management during pregnancy requires a coordinated multidisciplinary approach - active IBD during pregnancy is associated with significantly worse maternal and fetal outcomes than well-controlled IBD; the risk of disease flare during pregnancy outweighs the theoretical risk of biologic exposure for most patients; ECCO and AGA guidelines explicitly support continuation of vedolizumab during pregnancy in patients with active or recently active disease; vedolizumab, as an IgG1 monoclonal antibody, undergoes active placental transfer primarily in the third trimester, with lower transfer rates than anti-TNF agents; coordinated IBD-obstetrics management - with regular symptom assessment, fecal calprotectin monitoring, and fetal growth surveillance - is the standard of care for pregnant IBD patients on biologics
- Psychological support is an evidence-based component of IBD management - IBD is associated with significantly elevated rates of anxiety and depression, which in turn are associated with worse disease outcomes, lower medication adherence, and reduced quality of life; cognitive behavioral therapy (CBT) has demonstrated efficacy in reducing disease-related anxiety and improving quality of life scores in IBD patients; integration of psychological support into the IBD management pathway is a marker of a comprehensive, patient-centered program
About Dr. Ran Zhihua
Dr. Ran Zhihua is the Director of the IBD Center at Renji Hospital, Shanghai Jiao Tong University School of Medicine - one of China's premier academic medical centers and a nationally designated IBD treatment center. One of China's foremost authorities on Crohn's disease and ulcerative colitis, Dr. Ran chairs national IBD clinical guidelines and runs one of the highest-volume biologics therapy programs in East Asia. His center's Treat-to-Target framework, multidisciplinary team structure, and therapeutic drug monitoring protocols set the standard for IBD management across China.
His clinical expertise spans:
- Biologic and small molecule therapy for moderate-to-severe IBD - individualized selection and optimization of vedolizumab, anti-TNF agents (infliximab, adalimumab), ustekinumab, and JAK inhibitors (tofacitinib, upadacitinib) for Crohn's disease and ulcerative colitis, with systematic therapeutic drug monitoring and proactive dose optimization to maximize durable remission rates
- Treat-to-Target IBD management - implementation of the STRIDE-II consensus framework with defined clinical, endoscopic, and biomarker endpoints, systematic monitoring at protocol-defined time points, and objective-driven therapy adjustment; Dr. Ran's center achieves mucosal healing rates that benchmark against the world's leading IBD programs
- IBD in special populations - management of IBD during pregnancy and lactation, in elderly patients, in patients with prior malignancy, and in patients with complex comorbidities requiring individualized biologic selection and safety monitoring; Dr. Ran's center has established dedicated IBD-obstetrics and IBD-oncology coordination pathways
- Refractory and complex IBD - management of steroid-dependent and steroid-refractory IBD, biologic-failure disease, fistulizing Crohn's disease, and IBD with extraintestinal manifestations; Dr. Ran's high-volume referral practice includes patients who have failed multiple lines of therapy at other centers
- IBD-related endoscopy and dysplasia surveillance - high-definition chromoendoscopy and targeted biopsy protocols for dysplasia surveillance in long-standing extensive colitis, with individualized surveillance intervals based on risk stratification
- National IBD guideline leadership - chair of China's national IBD clinical practice guidelines, ensuring that evidence-based standards for biologic therapy, monitoring, and multidisciplinary management are implemented across the country's IBD treatment network
The Case That Showed What Precision IBD Management Looks Like
The Situation
A 32-year-old HR manager. Fourteen months of mucous bloody diarrhea, now 6-8 bowel movements per day with tenesmus and nocturnal diarrhea. Extensive ulcerative colitis (pancolitis) confirmed on colonoscopy - Mayo endoscopic score 3. Mesalazine 3 g/day failed. Topical enemas failed. Prednisolone induced remission but relapse occurred every time the dose fell below 15 mg - classic steroid dependence. CRP 18 mg/L; fecal calprotectin 1050 micrograms per gram; hemoglobin 102 g/L. Fertility plans within two years. MDT consensus: biologic escalation indicated; agent selection must prioritize gut selectivity and pregnancy safety. One question: is there an IBD specialist with the biologic expertise, the monitoring infrastructure, and the multidisciplinary network to achieve mucosal healing in this patient while protecting her fertility plans?
The Assessment
Dr. Ran reviewed Ms. Liu's complete workup - the colonoscopy images and histology, the laboratory results, the steroid exposure history, and the reproductive timeline. He reviewed the biologic options systematically: anti-TNF agents would be effective but carry higher systemic immunosuppression and a higher placental transfer rate in the third trimester; vedolizumab's gut selectivity, lower placental transfer rate compared to anti-TNF agents, and the growing body of pregnancy safety data made it the preferred agent for a patient planning conception within two years.
He designed a coordinated pathway from the outset: vedolizumab induction with a short steroid bridge, Treat-to-Target monitoring at weeks 14 and 30, therapeutic drug monitoring at week 22, and a pre-conception IBD-obstetrics planning session with the reproductive endocrinology team.
He explained his approach to Ms. Liu directly:
"Your disease is active across your entire colon, and the steroids are not a solution - they are a bridge that has gone on too long. Vedolizumab works in the gut specifically, which means it does not suppress your immune system the way other biologics do. The pregnancy safety data are strong - the guidelines support continuing it during pregnancy in patients like you. Our goal is not just to get your symptoms under control. It is to heal the lining of your colon, normalize your inflammatory markers, and get you to a place where you can plan your pregnancy from a position of disease control, not disease activity."
The Treatment
Dr. Ran initiated vedolizumab 300 mg IV at weeks 0, 2, and 6, with a short-course IV methylprednisolone bridge (40 mg/day for 5 days, rapidly tapered to zero within 7 days) to manage the induction gap while vedolizumab reached therapeutic levels. The steroid bridge was designed to be brief and complete - no ongoing steroid exposure.
The Treat-to-Target framework defined the monitoring schedule: week 14 clinical assessment (target: Mayo score 2 or below, symptom remission), week 22 therapeutic drug monitoring (target: trough concentration 10-20 micrograms per mL, anti-drug antibody negative), and week 30 colonoscopy (target: Mayo endoscopic score 0-1, mucosal healing).
At week 22, Ms. Liu's vedolizumab trough concentration was 17.2 micrograms per mL - within the therapeutic range - and anti-drug antibodies were undetectable. Drug exposure was adequate; immunogenicity was low. The dose was maintained at 300 mg every 8 weeks.
Alongside the biologic therapy, the team implemented a low-FODMAP dietary transition, avoided NSAIDs and broad-spectrum antibiotics, and integrated cognitive behavioral therapy for disease-related anxiety. Ms. Liu's IBDQ quality of life score rose from 112 to 156 over the course of treatment.
The Recovery
By week 8, Ms. Liu's bowel frequency had fallen to 2-3 movements per day with no blood or mucus. Her Mayo score had dropped to 4. Steroids had been completely stopped.
At her week 30 colonoscopy, the transformation was documented: Mayo endoscopic score 1 - only mild, localized erythema remaining in a colon that had been diffusely ulcerated eight months earlier. Fecal calprotectin had fallen from 1050 to 48 micrograms per gram. Hemoglobin had risen to 126 g/L; albumin to 41 g/L. Mucosal healing had been achieved.
At 12 months, Ms. Liu conceived. Her pregnancy was managed jointly by Dr. Ran's IBD team and the high-risk obstetrics unit - symptom assessment, fecal calprotectin monitoring, and fetal growth surveillance every four weeks throughout gestation. Vedolizumab was continued. There were no flares during pregnancy. The mode of delivery was determined by obstetric indications, not IBD contraindications.
At her 24-month follow-up, six months after delivery, Ms. Liu had resumed maintenance vedolizumab. Her Mayo score was 0. She had returned to full-time work. She was training for a half-marathon.
She sent a message to CMCS on the morning of her 24-month review. She wrote: "I used to think I had to choose between my health and my life. Dr. Ran showed me I didn't have to choose."
Outcome Summary
- ✅ Mucosal healing achieved at week 30 - Mayo endoscopic score reduced from 3 to 1; fecal calprotectin normalized from 1050 to 48 micrograms per gram; hemoglobin 102 to 126 g/L; albumin 36 to 41 g/L
- ✅ Complete steroid cessation by week 8 - short-course IV methylprednisolone bridge completed within 7 days; no ongoing steroid exposure after week 8; steroid dependence resolved
- ✅ Therapeutic drug monitoring confirmed optimal exposure - vedolizumab trough 17.2 micrograms per mL at week 22 (therapeutic range 10-20); anti-drug antibodies undetectable; dose maintained without adjustment
- ✅ Successful pregnancy with no IBD flare - conception at 12 months; vedolizumab continued throughout pregnancy under joint IBD-obstetrics management; no disease flare during gestation; healthy delivery
- ✅ Mayo score 0 at 24 months - complete endoscopic remission maintained at 24-month follow-up; no opportunistic infections or biologic-related adverse events throughout the treatment course
- ✅ Quality of life fully restored - IBDQ score 112 to 156 during treatment; returned to full-time work and half-marathon training at 24 months
- ✅ World-class outcome at a fraction of the cost - vedolizumab induction and maintenance with Treat-to-Target monitoring, therapeutic drug monitoring, and coordinated IBD-obstetrics management in Shanghai at a fraction of US or European costs
"She was 32. Steroid-dependent pancolitis. Fourteen months of bloody diarrhea. Two failed medications. A plan to start a family within two years. Dr. Ran Zhihua at Renji Hospital selected vedolizumab for its gut selectivity and pregnancy safety profile, built a Treat-to-Target monitoring pathway around her, and coordinated her care with reproductive endocrinology and high-risk obstetrics. At 30 weeks, her colonoscopy showed mucosal healing. At 12 months, she was pregnant. At 24 months, she had delivered a healthy baby, returned to full-time work, and was training for a half-marathon - with Mayo score 0 and no flares."
Why Shanghai for IBD Biologic Therapy?
- World-class outcomes at a fraction of the cost - vedolizumab induction and maintenance with Treat-to-Target monitoring, therapeutic drug monitoring, and multidisciplinary IBD management in Shanghai at a fraction of what it would cost in the US or Europe, with access to the same biologic agents, monitoring platforms, and evidence-based protocols used at the world's leading IBD centers
- High-volume IBD biologics program with systematic TDM - Dr. Ran's IBD Center at Renji Hospital is one of the highest-volume biologics programs in East Asia; the center's systematic therapeutic drug monitoring infrastructure - with defined trough concentration targets, anti-drug antibody testing, and proactive dose optimization - achieves sustained remission rates that benchmark against international standards
- Treat-to-Target as the institutional standard - many IBD programs manage symptoms without systematic endoscopic and biomarker monitoring; Dr. Ran's center implements the STRIDE-II Treat-to-Target framework for every patient, with protocol-defined colonoscopy and fecal calprotectin endpoints that ensure mucosal healing - not just symptom control - is achieved and documented
- Dedicated IBD-obstetrics coordination pathway - IBD management during pregnancy requires expertise that is not universally available; Dr. Ran's center has established a dedicated coordination pathway with reproductive endocrinology and high-risk obstetrics, ensuring that patients with fertility plans receive individualized biologic selection, pre-conception counseling, and joint antenatal monitoring that protects both maternal disease control and fetal outcomes
- National guideline leadership translating directly into clinical practice - Dr. Ran's role as chair of China's national IBD clinical guidelines means that his center's practice defines the evidence-based standard of care for IBD management across the country; patients treated at Renji Hospital's IBD Center receive care that reflects the current frontier of inflammatory bowel disease medicine
How CMCS Supports International Patients Seeking IBD Treatment in Shanghai
- 🏥 Specialist access - direct connection to Dr. Ran Zhihua and Renji Hospital's IBD Center, including priority appointment coordination for patients with urgent or complex presentations
- 📋 Colonoscopy reports, histology, imaging, laboratory results, medication history, and prior biologic exposure records translation and coordination
- 🗣️ On-site medical interpretation at every consultation, infusion, and follow-up
- ✈️ Travel and logistics coordination - visa, accommodation, airport transfers
- 📞 24/7 concierge support from first inquiry through every stage of treatment
- 🔄 Post-treatment follow-up - infusion scheduling coordination, therapeutic drug monitoring support, colonoscopy surveillance coordination, and long-term IBD management support
📢 Subscribe to China Medical Concierge - Shanghai (CMCS)
We're delighted to offer you trusted medical tourism and personalized medical concierge services, giving you and your loved ones an extra pathway to quality care from China.
💬 Got questions? Drop a comment or DM us - we're always here to help!
📢 Have your own incredible medical story in China? Share it with us in the comments below!
#ChinaMedicalTour #AffordableHealthcare #MedicalTourismChina #ChinaHealthcare #MedicalConcierge #IBD #UlcerativeColitis #Biologics #RanZhihua #RenjiHospital
🤝 Connect With CMCS
Struggling with long medical waitlists? Facing barriers to overseas treatment? China Medical Concierge - Shanghai (CMCS) helps international patients access premium medical care in Shanghai's top public and private hospitals, with end-to-end personalized support.
Contact us for international patient support:
📧 contract@medicalsh.com | 🌐 medicalsh.com
0 commenti